3. Exosomes in Cardiac Physiology and Pathology
As a matter of fact, exosome-mediated crosstalk amongst various cell types in heart tissues have been highlighted to play crucial role in the maintenance of cardiac homeostasis, as well as in the pathogenesis of cardiac diseases [
27,
30]. It is well recognized that in response to various stresses, heart tissue undergoes cardiac remodeling and development of cardiac hypertrophy, apoptosis, and fibrotic responses, which eventually contribute to HF [
31,
32]. Albeit, understanding the molecular intricacies underlying cardiac remodeling is one of the main challenges in cardiovascular medicine. However, it has been highlighted that these responses, in part, involves vesicle-mediated cellular cross talk among cardiomyocytes and other cells in the myocardium [
33,
34]. Reports have shown that cardiac cells under stress have increased secretion of exosomes and the exosomal content/composition are also altered; all these aspects eventually activate or suppress various molecular signaling in the recipient cells [
30,
35]. Interestingly, Lyu and group have highlighted that cardiac fibroblast (CF)-derived exosomes enhanced Renin–Angiotensin System (RAS) signaling in cardiomyocytes; and it was found that attenuation of these exosome secretion considerably reversed Angiotensin II-induced cardiac injuries [
36]. Similarly, researchers have highlighted that CF-derived exosomes, which were plausibly enriched with miRNAs, ensues in induction of hypertrophic responses[
37]; whereas Yang et al., highlighted that exosomes derived from cardiomyocytes ensued in cardiac fibrosis through myocyte-fibroblast cross-talk [
38]. Li and group has shown that plasma exosomal seemingly regulates inflammatory responses during cardiopulmonary bypass surgery through plausible involvement of miR-223 [
39]. These studies explicitly highlighted the importance of exosomes in cardiac homeostasis and disease biology. In addition to playing an imperative role in maintaining cardiac homeostasis and pathophysiology; they have been highlighted to endow with potentials to revolutionize cell based therapeutic intervention against CVDs by being a potential means of cell free therapeutic strategy [
40]. Accordingly, in the subsequent section, newer area into the exploration of exosomes as cell free therapeutic intervention, intriguing drug delivery platform, and novel biomarkers for CVDs had been discussed.
4. Exosomes-Based Therapeutic Interventions against CVDs
Over the years, efforts have continuously been laid down to develop effective therapeutic strategies that would certainly improve the quality of the CVDs clientele. Newer therapeutic strategies are being developed, focusing not only to protect the heart tissue but also to regenerate the myocardium. To this end, accumulating evidence has highlighted the potential of stem cell therapies against CVDs; nevertheless, as of yet, these therapies refrain from showing promising results in clinical trials. Meanwhile, it has been envisaged that most of the favorable outcomes of the transplanted cells were usually indirect. Reports have highlighted that when mesenchymal stem cells (MSCs) were injected in animal model, only 6% of the injected cells were finally being retained in the infarct site [
41]. It has been argued that the transplanted cells may secrete various factors/mediators, including extracellular vesicles (EVs), exosomes, growth factors, etc., that might actually play important role in mediating the beneficial effects of cell therapy. This has reinforced the holistic and emerging view of exosomes as an alternative and viable therapy. Nevertheless, despite many promising studies, the precise mechanism of exosome induced perturbations in the recipient cell still remains poorly understood. Meanwhile, taking note of other aspects, a forward leap in the arena of exosomes-based therapeutic interventions has been development of synthetic exosomes with drug delivery potentials, especially the bio-engineered targeted exosomes as detailed in the subsequent sections. Interestingly, many studies clearly indicated that exosomes in general and engineered exosomes in particular have opened newer frontier in arena of intriguing drug delivery platform and there is a high probably that these strategies may find a prosperous status in biomedical sciences in near future.
(A) Exosomes as Cell-Free Therapeutic Strategies against CVDs
Owing to their various intriguing characteristics, they are increasingly being employed as a means of cell-free therapeutic interventions for myriads of obstinate diseases, including CVDs [
40]. Accumulating evidence has reported that exosomes from cardiosphere-derived stem cells (CDCs) have been shown to simulate the therapeutic effects of CDCs to a large extend in animal models of heart disease [
42,
43,
44,
45]. They have been underscored to modulate cardiomyocyte hypertrophic and apoptotic responses, induce angiogenesis, and stimulate endogenous cardiomyocyte proliferation [
46]. Interestingly, Zhu and the group have reported the application of human umbilical cord mesenchymal stem cell (UMSC) derived exosomes against aging related cardiac complications. In their study, the authors have ascertained that UMSC derived exosomes through the release of novel metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) lncRNA suppressed aging-related cardiac complications through subsequent attenuation of NF-κB/TNF-α signaling cascade [
47]. Further, it has been highlighted that exosomes produced by CDCs have been demonstrated to stimulate myocardial regeneration via transportation of miRNA to the cardiac cells [
42,
44,
48]. In addition, Limana and group have demonstrated that exosomal from pericardial fluid considerably improved myocardial performance following myocardial infarction (MI) and has ascertained that exosomal protein clustering, an important mediator of TGF-β signaling, was plausibly responsible for the underlying cardiac protective effects [
49]. Interestingly, these discoveries rationalize the use of exosomes as intriguing therapeutic intervention against CVDs.
(B) Bio-Engineered Exosomes as Next-Generation Therapeutic Intervention
As a matter of fact, exosomes have been comprehended as an important cellular communication agent embodying potentials to transport diverse range of molecular entities within the biological system [
50,
51]. Because of their intrinsic ability to delivery molecular entities, they are considered as a promising drug delivery system (DDS) for various bioactive compounds and small molecular drugs and has been demonstrated to considerably improve their pharmacological properties against various diseases in general, and CVDs in particular. Compared with conventional drug delivery platforms, such as micelles, microemulsion, nanospheres, liposomes, and metallic nano-particulate system; exosomes offer many desirable advantages, such as lower toxicity, lower immunogenicity, high stability in circulation, better biocompatibility, and biological barrier permeability, which makes them attractive platforms for efficient delivery of therapeutic agents. Interestingly, exosomes have been used to deliver therapeutic drug and small molecules to many tissues, including the heart [
52,
53,
54,
55,
56,
57,
58]. In fact, in recent years, engineered exosomes has been harnessed for targeted co-delivery of chemotherapeutics drug and RNA in fight against various diseases [
59]. Nevertheless, exosomes in analogy with other drug delivery platforms also suffer from the drawback of endocytosis by the mononuclear phagocyte system (MPS). It has been highlighted that, when unmodified/neat exosomes were administrated systemically in animal model, they were found preferentially accumulated in the MPS organs such as liver, kidney, and spleen, which, thereafter, were rapidly cleared by bile excretion, renal filtration, and/or were phagocytized, leading to minimal accumulation of the therapeutics in the intended tissues or organs and undue delivery to un-intended tissues [
60]. This bio-distribution profile and off-target effects limited the clinical acceptability of the unmodified exosomes [
60,
61,
62]. Therefore, attempts have been made to modify exosomes for effective targeting to desired tissue. One method that has been harnessed is modification of exosomes with homing ligands or peptides, which confers them targeting capability to tissues or organs carrying the corresponding receptors. In cardiovascular system, several homing ligands/peptides are been explored for targeted therapy [
52,
63,
64,
65]. Moreover, many peptides endowed with homing potential to different cardiovascular systems, such as normal cardiomyocyte, ischemia/reperfusion injured cardiomyocytes, the vascular system etc. offers exciting avenues for exosome targeting ligands [
63,
64,
66,
67,
68]. Interestingly, exosomes can be derived from an individual differentiated hematopoietic stem cells (HSC) and used for tissue-targeted cargo delivery through the expression of tissue-specific peptides. Thereafter, by loading miRNA and/or siRNA of the targeted gene, these modified tissue targeted exosomes can selectively regulate gene expression in the specific tissue corresponding to the homing peptides. Interestingly, Vandergriff et al., developed an infarct-targeting exosomes, through the use of cardiac homing peptide (CHP: CSTSMLKAC (IMTP)) to increase the efficacy and decrease the effective dose of intravenously delivered exosomes [
63,
64]. They basically conjugated cardiac stem cell-derived exosomes with cardiac homing peptide IMTP through a click chemistry approach using dioleoylphosphatidyl ethanolamine N-hydroxy succinimide linker. Interestingly, increased retention of the IMTP-exosomes within the ischemia/reperfusion injured heart tissues were observed to a considerable extent and improvement in cardiac function was also achieved thereof [
69]. Similarly, molecular cloning and lentivirus packaging techniques were employed to engineer exosomal enriched membrane protein, i.e., Lamp2b fused with ischemic myocardium-targeting peptide IMTP. Such a fusion resulted in peptides being displayed on the surface of exosomes. Interestingly, these IMTP-exosomes displayed efficient internalization by hypoxia-injured embryonic cardiomyocyte H9c2 cells compared to blank-exosomes and subsequent increased accumulation in ischemic heart tissue were also obtained [
65]. Meanwhile, attenuation of the inflammatory, apoptotic, and fibrotic responses was observed and enhanced vasculogenesis, and improved cardiac function were detected following IMTP-exosome treatment in ischemic heart. Further, Mentkowski and Lang bio-engineered a cardiomyocyte targeted exosomes that demonstrated improved cardiac retention in in vivo system [
52]. Further, Mentkowski and Lang bio-engineered a cardiomyocyte targeted exosomes that demonstrated improved cardiac retention in an in vivo system [
52]. To this end, the researcher selected a cardiomyocyte-specific peptide (CardioMyocyte Peptide (CMP): WLSEAGPVVTVRALRGTGS) [
63,
70]; which has proven ability to specifically target cardiac tissues [
53,
69,
71,
72]. The researcher ligated this CMP to the extra-exosomal N-terminus of Lamp2b. Interestingly, these cardiac-targeted CDC exosomes showed improved uptake into cardiac cells in an in vitro model; thereby leading to improved cardiac retention in in vivo system and, eventually, reduced cardiac apoptosis [
52]. It has been envisaged that decorating the surfaces of the exosomes with homing ligand/entities will certainly reduce the time exosomes require to reach the therapeutic concentration in targeted tissues, and will considerably reduce the off-target effect, thereby leading to enhanced therapeutic potential. For detailed outline for the generation and isolation of the engineered exosomes; readers are advised to go through various previously published articles [
52,
59,
65,
68,
69,
73]. An overview of procedures for generation of engineered exosomes for specific targeting of the therapeutic molecules to desired tissue along with the workflow of differential ultracentrifugation for the isolation of the exosome are represented in
Figure 2.
Figure 2. Representative figure highlighting the procedures for generation of engineered/modified exosomes for specific targeting of the therapeutic molecules to desired tissue (
A) along with the workflow of differential ultracentrifugation for exosome isolation (
B). The figures are prepared with the BioRender Software (
biorender.com).
5. Exosomes as Prospective Biomarkers for CVDs
Accumulating evidences have shown that exosomes contain diverse biological contents that plausibly is a reflection of a particular state of the system [
74]. Along these lines, the vast repertoire of molecular entities that are packaged within exosomes, their versatile appearance in nearly all body fluids marks their potential candidature for prospective novel non-invasive biomarkers [
75].
Amongst the exosomes content, exosomes proteins and RNA molecules especially miRNA are increasingly been reported as promising biomarkers [
76]. In fact, exosomal miRNAs have been the most studied for their role as novel biomarkers for CVDs. A distinct miRNA profile has been reported by various workers in CVD patients compared to normal individuals. To this end, Matsumoto and group reported that p53-responsive circulating exosomes miRNAs viz. hsa-miR-192, hsa-miR-194 and hsa-miR-34a, were considerably upregulated in the serum of acute MI clienteles that have experienced development of HF in short period. This study highlights the importance of these exo-miRNA as plausible prognostic biomarkers for acute MI [
77]. Further, studies have also shown that serum exosomal miR-9 and miR-124 levels were significantly higher in stroke patients. Concomitantly, circulating exosomal miR-9 and miR-124 might be promising biomarkers for stroke diagnosis [
78]. Further, Gidlof and colleagues have demonstrated that upregulation of plasma levels of hsa-miR-208b and hsa-miR-499-5p corresponded to increase in the risk of HF, highlighting their prognostic biomarker potential [
79].
Further, studies have envisaged the importance of various other exosomal proteins for prospective biomarkers for CVDs. To this end, Pironti et al., have reported that circulating exosomes induced by cardiac pressure overload contain functional angiotensin II type 1 receptors (AT
1Rs); they have envisaged that the transfer of AT
1Rs plausibly deteriorates cardiac function during blood pressure (BP) overload, thus, could help in analyzing the prognosis of the pressure overload diseased patients [
80]. Similarly, the adenosine 2A receptors and dopamine receptors have also been packed within EVs and transferred to other cells, leading to an increase in BP and cardiac remodeling thereof [
81]. These findings seemingly highlight for usage of these exosomal proteins as prognostic biomarkers for hypertension clienteles.